Viagra may reduce symptoms of multiple sclerosis

The National Multiple Sclerosis Society estimates that about 400,000 people have the disease that causes pain in the muscles and can lead to difficulty walking and talking. Usually, a person is diagnosed with multiple sclerosis between 20 and 50 years of age, but multiple sclerosis has been diagnosed in children and in the elderly. Multiple sclerosis is twice as likely to occur in Caucasians as in any other group and women are twice as likely as men to be affected by multiple sclerosis earlier in life.

Viagra, the wonder drug for men battling erectile dysfunction, may help MS patients deal with their symptoms.  A study done by Universitat Aut??noma de Barcelona shows a complete recovery occurs in 50% of the animals after eight days of Viagra treatment. Researchers are confident that clinical trials will begin soon and show similar results in humans.

The “little blue pill” has made headlines since it hit the market in 1998.  Millions of men have taken the medication to help with erectile dysfunction.  The medication is known to help men achieve and keep an erection for sex.  However, that is not its only application. Several other studies have show Viagra can help with heart problems, and even help women conceive.

Viagra is part of a group of vasodilator drugs, which has shown great results in treating sexually issues, but doctors believe the “talents” of Viagra could reach far beyond fun in the bedroom.

“After battling MS for about a decade now, I would welcome any advancement in the field,” Ariel Svelden said.  “I am on medication right now that does help manage the disease, but if there was another option, I would love to see if it would work better for me.”

About lisaf As a journalist Lisa enjoys writing about a variety of topics. Over the course of the last ten years she has been involved in television news as well as print and online publications. Medical news has always been a favorite for this native New Yorker because she gets to stay on top of the latest developments in a rapidly changing field.

No comments: